Baxter G, Kennett G, Blaney F, Blackburn T
Neuroscience Research Department, SmithKline Beecham Pharmaceuticals, Harlow, UK.
Trends Pharmacol Sci. 1995 Mar;16(3):105-10. doi: 10.1016/s0165-6147(00)88991-9.
The current classification for 5-HT2 receptors accommodates three subtypes. In addition to the originally defined 5-HT2 receptor, sanctuary is now provided for the structurally related 5-HT1c receptor (now 5-HT2c) and at least one atypical 5-HT receptor subtype. The strong functional union of this family is reflected in the paucity of ligands that will discriminate between its subtypes and prompts some re-evaluation of the activities of compounds which may now be regarded as nonselective for the receptor subtypes in this class. In this article, Gordon Baxter and colleagues examine the pharmacology of both officially recognized and atypical 5-HT2 receptor subtypes. A number of novel selective agents are highlighted, some of which may prove useful for 5-HT2 receptor classification and, ultimately, clarify the mechanistic basis for current and future therapeutic strategies which target this receptor family.
目前对5-羟色胺2(5-HT2)受体的分类包含三种亚型。除了最初定义的5-HT2受体外,现在还涵盖了结构相关的5-HT1c受体(现称为5-HT2c)以及至少一种非典型5-HT受体亚型。该受体家族强大的功能统一性体现在能够区分其亚型的配体数量稀少,这促使人们对一些化合物的活性进行重新评估,这些化合物现在可能被认为对该类受体亚型无选择性。在本文中,戈登·巴克斯特及其同事研究了官方认可的和非典型的5-HT2受体亚型的药理学。文中重点介绍了一些新型选择性药物,其中一些可能对5-HT2受体分类有用,并最终阐明当前及未来针对该受体家族的治疗策略的机制基础。